Validation of Two New Questionnaires for Dupuytren's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to validate two newly developed questionnaires for Dupuytren's Disease. The objective is to develop a patient specific outcomes tool for Dupuytren's Disease. While there are standard and validated questionnaire instruments used to measure health related quality of life and function, they do not address patient specific issues. The investigators will also pilot a treatment/disease specific satisfaction questionnaire for Xiaflex use for Dupuytren's Disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Registry of Dupuytren's Contracture Treatment Outcomes

NCT01567397

Dupuytren's Disease

COMPLETED

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

NCT02165111

Scleroderma Raynaud's Syndrome

COMPLETED PHASE3

Repurposing Anti-TNF for Treating Dupuytren's Disease

NCT03180957

Dupuytren's Disease

COMPLETED PHASE2

Collagenase in the Treatment of Dupuytrens Disease

NCT00260429

Dupuytren's Disease

COMPLETED PHASE3

Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis

NCT00043706

Systemic Sclerosis Scleroderma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dupuytren's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject has a diagnosis of Dupuytren's Disease in at least one finger
* Patients will be 35 years of age or older
* Patients will be able to read, speak, and understand English
* Patients will be able to provide voluntary written consent to participate

Exclusion Criteria

* Female patients who are nursing or pregnant, or plan to become pregnant during the treatment phase.
* Patient has a chronic muscular, neurological or neuromuscular disorder that affects the hands.
* Patient has a known allergy to collagenase or any other excipient of XIAFLEX.
* Patient has received any collagenase treatments before the first dose of XIAFLEX.
* Any history of or current medical condition which in the investigator's opinion would make the subject unsuitable for enrollment in the study

Minimum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No